Gujarat Kidney Appoints Auditors, OKs H1 FY26 Results Amid Regulatory Review

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorIshaan Verma|Published at:
Gujarat Kidney Appoints Auditors, OKs H1 FY26 Results Amid Regulatory Review
Overview

Gujarat Kidney And Superspeciality Limited's board approved H1 FY26 and FY25 financial results, reporting consolidated profits of ₹1,151.97 lakh and ₹1,276.52 lakh respectively. The meeting also appointed Mr. Dharmendra Bhaliya as Secretarial Auditor and Mr. Siddharth Atulbhai Shah as Internal Auditor for FY25-26. Actions from a prior board meeting were ratified due to an inadvertent misunderstanding of SEBI (LODR) Regulations.

Gujarat Kidney And Superspeciality Limited: Financial Update and Auditor Appointments

Gujarat Kidney And Superspeciality Limited reported a consolidated profit after tax of ₹1,151.97 lakh (₹11.52 crore) for the half-year ended September 30, 2025. Total income for the same period was ₹2,828.52 lakh (₹28.29 crore).

The company's board met on March 19, 2026, to approve these financial results and confirm key appointments. Mr. Dharmendra Bhaliya has been appointed as the Secretarial Auditor, and Mr. Siddharth Atulbhai Shah as the Internal Auditor, for the financial year 2025-26.

During the meeting, the board also ratified actions taken at a previous session on February 14, 2026. This step was necessary to rectify an inadvertent misunderstanding concerning SEBI (Listing Obligations and Disclosure Requirements) Regulations.

Company Background and Past Reporting

Gujarat Kidney operates a chain of multi-speciality hospitals across Gujarat, focusing on secondary and tertiary healthcare services. The company recently completed its Initial Public Offering (IPO) in late 2025, with the raised capital intended for acquisitions, expansion of its hospital network, and debt repayment.

This latest regulatory ratification follows past reporting complexities. The National Company Law Tribunal (NCLT) had previously permitted the company to voluntarily revise its Board's Reports and financial notes for fiscal years 2021-22 through 2023-24.

Detailed Financials

For the full financial year ended March 31, 2025, Gujarat Kidney's consolidated profit after tax was ₹1,276.52 lakh (₹12.77 crore), with total income at ₹4,039.70 lakh (₹40.40 crore).

On a standalone basis, the company recorded a profit of ₹620.10 lakh (₹6.20 crore) for the half-year ended September 30, 2025, on total income of ₹2,110.91 lakh (₹21.11 crore). Standalone profit for the full FY25 stood at ₹910.90 lakh (₹9.11 crore), with income of ₹3,528.11 lakh (₹35.28 crore).

Market Context

Gujarat Kidney operates within the competitive healthcare services sector. Its peers include prominent names such as Apollo Hospitals Enterprise Ltd., Max Healthcare Institute Ltd., Fortis Healthcare Ltd., and Narayana Hrudayalaya Ltd.

Investor Focus

The recent board approvals provide shareholders with clarity on the company's financial performance for the first half of FY26 and FY25. The appointment of auditors for FY25-26 ensures continued scrutiny and compliance. Investors will likely monitor future announcements for adherence to governance standards and SEBI regulations. Tracking the company's financial trajectory, particularly growth initiatives funded by the IPO, will be important.

Disclaimer:This content is for informational purposes only and does not constitute financial or investment advice. Readers should consult a SEBI-registered advisor before making decisions. Investments are subject to market risks, and past performance does not guarantee future results. The publisher and authors are not liable for any losses. Accuracy and completeness are not guaranteed, and views expressed may not reflect the publication’s editorial stance.